Annual report pursuant to Section 13 and 15(d)

Intangible Assets and Impairment of Long-Lived Assets (Tables)

v3.23.1
Intangible Assets and Impairment of Long-Lived Assets (Tables)
 12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
    Remaining
Amortization
Period		   As of December 31, 2022     As of December 31, 2021  
    in Years at
December 31,
2022		   Gross
Asset
Value		     Accumulated
Amortization		     Net
Carrying
Value		     Gross
Asset
Value		     Accumulated
Amortization		     Net
Carrying
Value		  
Licensed patents   13.5   $ 596,259     $ (142,654 )   $ 453,605     $ 603,919     $ (110,759 )   $ 493,160  
Technology license   16.6     1,485,159       (279,906 )     1,205,253       1,658,550       (202,797 )     1,455,753  
        $ 2,081,418     $ (422,560 )   $ 1,658,858     $ 2,262,469     $ (313,556 )   $ 1,948,913  

 
Schedule of future amortization related to intangible assets
For the Years Ending December 31,      
2023   $ 109,489  
2024     109,489  
2025     109,489  
2026     109,489  
2027     109,489  
Thereafter     1,111,413  
    $ 1,658,858  

 
Schedule of goodwill activity
    CBR
Pharma
Goodwill		     180 LP
Goodwill		     Consolidated
Goodwill		  
Balance, December 31, 2021   $ 23,749,631     $ 13,238,255     $ 36,987,886  
Currency translation     (664,353 )    
-
       (664,353 )
                         
Balance, March 31, 2022     23,085,278       13,238,255       36,323,533  
Currency translation     (1,734,582 )    
-
       (1,734,582 )
                         
Balance, June 30, 2022     21,350,696       13,238,255       34,588,951  
Currency translation     (1,750,386 )    
-
       (1,750,386 )
Balance before impairment     19,600,310       13,238,255       32,838,565  
Impairment of goodwill     (11,264,612 )     (7,608,238 )     (18,872,850 )
                         
Balance, September 30, 2022     8,335,698       5,630,017       13,965,715  
Currency translation     708,713      
-
       708,713  
Balance before impairment     9,044,411       5,630,017       14,674,428  
Impairment of goodwill     (9,044,411 )     (5,630,017 )     (14,674,428 )
                         
Balance, December 31, 2022   $
-
     $
-
     $
-
  

 

    CBR
Pharma IP
R&D Assets		     180 LP IP
R&D
Assets		     Consolidated
IP R&D
Assets		  
Balance, December 31, 2021   $ 1,632,780     $ 10,943,000     $ 12,575,780  
Currency translation     (45,674 )    
-
       (45,674 )
                         
Balance, March 31, 2022     1,587,106       10,943,000       12,530,106  
Currency translation     (119,252 )    
-
       (119,252 )
                         
Balance, June 30, 2022     1,467,854       10,943,000       12,410,854  
Currency translation     (120,338 )    
-
       (120,338 )
                         
Balance, September 30, 2022     1,347,516       10,943,000       12,290,516  
Currency translation     114,568      
-
       114,568  
Balance before impairment     1,462,084       10,943,000       12,405,084  
Impairment of IP R&D assets     (1,462,084 )     (1,880,000 )     (3,342,084 )
                         
Balance, December 31, 2022   $
-
     $ 9,063,000     $ 9,063,000